MHC Class-I Loss and Cancer Immune Escape, 1st ed. 2019
Advances in Experimental Medicine and Biology Series, Vol. 1151

Author:

Language: English
Cover of the book MHC Class-I Loss and Cancer Immune Escape

Subjects for MHC Class-I Loss and Cancer Immune Escape

105.49 €

In Print (Delivery period: 15 days).

Add to cartAdd to cart
MHC Class-I Loss and Cancer Immune Escape
Publication date:
101 p. · 17.8x25.4 cm · Paperback

147.69 €

In Print (Delivery period: 15 days).

Add to cartAdd to cart
MHC Class I Loss and Cancer Immune Escape
Publication date:
101 p. · 17.8x25.4 cm · Hardback

 

This book is about the escape strategies used by cancer cells to avoid the immune response of the host. The main characters of this story are the ?Antigen Presenting Molecules? and the ?T Lymphocytes?. The former are known as the Major Histocompatibility Complex (MHC): the H-2 and the HLA molecules. The latter are a subgroup of white cells travelling all over our body which are capable to distinguish between ?self and non self?.

Readers will know from the inside about the history of the HLA genetic system and will discover how T lymphocytes recognize and destroy cancer cells. One of the key important questions is: Why tumors arise, develop and metastasize? This book tries to answer this question and will explain how cancer cells become invisible to killer T lymphocytes. The loss of the HLA molecules is a major player in this tumor escape mechanism.

Cancer immunotherapy is aimed at stimulating T lymphocytes to destroy tumor cells. However, the clinical response rate is not as high as expected. The molecular mechanisms responsible for MHC/HLA antigen loss play a crucial role in this resistance to immunotherapy. This immune escape mechanism will be discussed in different types of tumors: lung, prostate, bladder and breast?ect. as well as melanoma and lymphoma.

This book will be useful to Oncologists, Pathologists and Immunologist that will enter this fascinating area of research. It will be also interesting for biologist, doctoral students and medical residents interested in ?Tumor Immunology?.   


Preface.- Introduction.- Mhc/Hla Class I Loss In Cancer Cells.- Hla Class-I Expression And Cancer Immunotherapy.-  Hla Class-Ii Expression In Human Tumors.- Index.


Prof. Federico Garrido is Professor of Immunology at the University of Granada Medical School and head of the Dept. of Clinical Analysis & Immunology at the Hospital Universitario Virgen de las Nieves, Granada, Spain. After obtaining his MD and PhD degrees from the University of Granada in 1974, Prof. Garrido went on as a postdoctoral fellow at the laboratory of Dr. Hilliard Festenstein at the London Hospital Medical College in London, investigating the immunogenetics of the MHC (H-2) system by typing mouse tumour cells for H-2 expression. After returning to Granada in 1981 he continued his research on HLA typing of human tumour tissues. Prof. Garridos research focuses on the expression of HLA antigens in tumours and the role that these molecules play on tumour evasion from the immune system.
The history of Tumor Immunology How cancer cells escape the immune response The new era of Cancer Immunotherapy